blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3421462

EP3421462 - HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2024
Database last updated on 16.11.2024
FormerThe patent has been granted
Status updated on  03.03.2023
FormerGrant of patent is intended
Status updated on  10.10.2022
FormerExamination is in progress
Status updated on  22.10.2021
FormerRequest for examination was made
Status updated on  05.07.2019
FormerThe application has been published
Status updated on  30.11.2018
Most recent event   Tooltip10.05.2024Lapse of the patent in a contracting state
New state(s): SI		published on 12.06.2024  [2024/24]
Applicant(s)For all designated states
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
[2023/21]
Former [2019/01]For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Inventor(s)01 / BRODNEY, Michael Aaron
100 Upland Avenue
Newton, MA 02461 / US
02 / DAVOREN, Jennifer Elizabeth
2456 Massachusetts Avenue 105
Cambridge, MA 02140 / US
03 / DOUNAY, Amy Beth
5725 Astoria Way
Colorado Springs, CO 80919 / US
04 / EFREMOV, Ivan Viktorovich
83 Payson Road
Chestnut Hill, MA 02467 / US
05 / GRAY, David Lawrence Firman
26 Orion Way
Groton, MA 01450 / US
06 / GREEN, Michael Eric
22 Ward Street
Apartment 2
Boston, MA 02127 / US
07 / HENDERSON, Jaclyn Louise
36 Highland Avenue Apt. 54
Cambridge, MA 02139 / US
08 / LEE, Chewah
35 Highland Drive
Wallingford, CT 06492 / US
09 / MENTE, Scot Richard
49 Arlmont Street
Arlington, MA 02476 / US
10 / O'NEIL, Steven Victor
2 Pear Grove
East Lyme, CT 06333 / US
11 / ROGERS, Bruce Nelsen
19 Lawndale Street
Belmont, MA 02478 / US
12 / ZHANG, Lei
75 Bourne Street
Auburndale, MA 02466 / US
 [2019/01]
Representative(s)Cohausz & Florack
Patent- & Rechtsanwälte
Partnerschaftsgesellschaft mbB
Bleichstraße 14
40211 Düsseldorf / DE
[2019/01]
Application number, filing date18180416.213.06.2014
[2019/01]
Priority number, dateUS201361840144P27.06.2013         Original published format: US 201361840144 P
[2019/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3421462
Date:02.01.2019
Language:EN
[2019/01]
Type: B1 Patent specification 
No.:EP3421462
Date:05.04.2023
Language:EN
[2023/14]
Search report(s)(Supplementary) European search report - dispatched on:EP15.10.2018
ClassificationIPC:C07D401/14, C07D405/14, C07D401/12, A61K31/513, A61K31/501, A61K31/497, A61P25/00, A61K31/444, A61K31/506
[2019/01]
CPC:
C07D401/14 (EP,US); A61K31/444 (EP,US); A61K31/501 (EP,US);
A61K31/506 (EP,US); A61K31/513 (EP,US); A61P13/12 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/06 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP,US);
A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP,US);
A61P25/30 (EP); A61P27/02 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P3/12 (EP);
A61P31/04 (EP); A61P37/02 (EP); A61P7/00 (EP);
A61P7/12 (EP); A61P9/04 (EP); A61P9/10 (EP);
A61P9/12 (EP); C07D401/12 (EP,US); C07D403/12 (US);
C07D405/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/32]
Former [2019/01]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:HETEROAROMATISCHE VERBINDUNGEN UND DEREN VERWENDUNG ALS DOPAMIN-D1-LIGANDEN[2019/01]
English:HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS[2019/01]
French:COMPOSÉS HÉTÉRO-AROMATIQUES ET LEUR UTILISATION EN TANT QUE LIGANDS D1 DE LA DOPAMINE[2019/01]
Examination procedure28.06.2019Amendment by applicant (claims and/or description)
28.06.2019Examination requested  [2019/32]
28.06.2019Date on which the examining division has become responsible
22.10.2021Despatch of a communication from the examining division (Time limit: M04)
28.02.2022Reply to a communication from the examining division
11.10.2022Communication of intention to grant the patent
21.02.2023Fee for grant paid
21.02.2023Fee for publishing/printing paid
21.02.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14739554.5  / EP3013813
Opposition(s)08.01.2024No opposition filed within time limit [2024/11]
Fees paidRenewal fee
17.12.2018Renewal fee patent year 03
17.12.2018Renewal fee patent year 04
17.12.2018Renewal fee patent year 05
13.06.2019Renewal fee patent year 06
15.06.2020Renewal fee patent year 07
14.06.2021Renewal fee patent year 08
13.05.2022Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
28.06.201803   M06   Fee paid on   17.12.2018
28.06.201804   M06   Fee paid on   17.12.2018
30.06.201805   M06   Fee paid on   17.12.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.04.2023
EE05.04.2023
LT05.04.2023
LV05.04.2023
MC05.04.2023
SI05.04.2023
SK05.04.2023
SM05.04.2023
IE13.06.2023
LU13.06.2023
IS05.08.2023
[2024/24]
Former [2024/21]AL05.04.2023
EE05.04.2023
LT05.04.2023
LV05.04.2023
MC05.04.2023
SK05.04.2023
SM05.04.2023
IE13.06.2023
LU13.06.2023
IS05.08.2023
Former [2024/15]AL05.04.2023
EE05.04.2023
LT05.04.2023
LV05.04.2023
MC05.04.2023
SK05.04.2023
SM05.04.2023
LU13.06.2023
IS05.08.2023
Former [2024/11]AL05.04.2023
EE05.04.2023
LT05.04.2023
LV05.04.2023
MC05.04.2023
SK05.04.2023
SM05.04.2023
IS05.08.2023
Former [2024/09]LT05.04.2023
LV05.04.2023
MC05.04.2023
SK05.04.2023
SM05.04.2023
IS05.08.2023
Former [2024/08]LT05.04.2023
LV05.04.2023
SK05.04.2023
SM05.04.2023
IS05.08.2023
Former [2024/01]LT05.04.2023
LV05.04.2023
IS05.08.2023
Former [2023/50]IS05.08.2023
Documents cited:Search[A]WO2013030665  (PURDUE PHARMA LP [US], et al);
 [AP]WO2014072881  (PFIZER [US])
by applicantWO9111172
 WO9402518
 WO9855148
 WO0035298
 US6106864
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.